SLC3A2 and cardiac hypertrophy: A shift of the myosin heavy chain ratio towards slower β-MHC, the growth in myocardial contraction time, a thickening of cardiomyocytes and a reduction in the sliding velocity of reconstituted thin filaments in an in vitro motility assay may point to the development of concentric cardiac hypertrophy.